A CMS official told those at TCT 2007 that the agency is unlikely to scale back coverage for drug-eluting stents, even in the wake of safety concerns, the Wall Street Journal reports. In February, CMS said it was considering restricting coverage for off-label uses of the products. But judging from comments by Marcel Salive, director of medical and surgical services in the agency's coverage and analysis group, that's probably not going to happen. Of course, not a whole lot of study of off-label patients has been done. In a few years, when more data is available, we'll see if the agency changes its mind.